Medtronic earns CE mark for Stealth AXiS robot platform in ENT surgery
June 8, 2026
Medtronic (NYSE:MDT) today announced the receipt of CE mark approval for its Stealth AXiS surgical system for ENT procedures.
Medtronic (NYSE:MDT) today announced the receipt of CE mark approval for its Stealth AXiS surgical system for ENT procedures.
A group of researchers at the Medical University of South Carolina (MUSC) has recently developed a new stem cell therapy with a remarkable ability to reverse new-onset type 1 diabetes (T1D) in a mouse model of the disease. The work is published in the journal Molecular Therapy.
The first human clinical trial of a universal Sarbeco coronavirus vaccine, developed by the University of Cambridge and spin-out DIOSynVax (DVX) Ltd, has shown that the vaccine is safe and has no significant side effects.
The new vaccine aims to produce an immune response that will protect against many pathogens—including some circulating among wild animals that might jump into humans in the future.
A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer Institute and professor of internal medicine at the University of Utah (the U), has found that a combination prostate cancer treatment could prevent the disease from progressing into a harder-to-treat form of cancer in select patients.
A new method for whole-genome sequencing of hantaviruses improves on today’s strategies for identifying outbreaks.
GE HealthCare has received FDA 510(k) clearance for MIM Contour ProtégéAI+ 2.0, an AI-enabled auto-contouring software designed to assist radiation oncology care teams with treatment planning.
Zepto Life’s FungiFlex mould panel is designed to identify 14 clinically important mould species based on cell free fungal DNA detected in plasma.
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received expanded CE mark for its automated insulin delivery (AID) systems.
Published today in Cell, the team applied machine learning to blood plasma protein data from more than 48,000 UK Biobank participants, using matched cancer registry records to identify those who later developed lung cancer.